Tag: Nordic Nanovector

March 17, 2017 Off

Nordic Nanovector kicks off phase 1 Betalutin study

By Dino Mustafić

Nordic Nanovector ASA has begin dosing patients in its Phase 1 Betalutin study, testing a CD37 targeting antibody-radionuclide conjugate, in patients with relapsed diffuse large B-cell lymphoma (DLBCL) who are ineligible for stem cell transplantation.